Public trial registry of the CCC-Munich

Trial AGO OVAR 22_YO39523_IMaGYN050

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
AGO OVAR 22_YO39523_IMaGYN050
World
Full title
:

Protocol Title: A phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer

World
Responsible organization
:
Frauenklinik Frauenklinik Ismaninger Str. 22 81675 München Germany Tum
Indications
Classification Code Description
- N64.9 Krankheit der Mamma, nicht näher bezeichnet
Trial design
World
Phase
:
III
Status
World
Status
:
Recruitment finished
Votes
World
Institutional review board - vote
:
Positive
World
Institutional review board - vote date
:
2017-12-13
Initiiation & lock
World
Date of lock (planned / actual)
:
Unknown / Unknown
Therapy
World
Therapy
:

Chemo - Therapieart: adjuvant

Participants
Function Prename Surname Organization
World Responsible contact Holger Bronger Frauenklinik Frauenklinik Ismaninger Str. 22 81675 München Germany Magnifier